abstract |
The present publication relates to certain (2S) -N - [(1S) -1-cyano-2-phenylethyl] -1,4-oxazepan-2-carboxamide compounds (including their pharmaceutically acceptable salts) that inhibit dipeptidyl peptidase activity. I (DPPI), their utility in the treatment and / or prevention of clinical conditions including respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), their use in treatment, the pharmaceutical compositions containing them, and procedures for preparation of such compounds. |